Tissue Immune Landscape of Graft Versus Host Disease After Allogeneic Stem Cell Transplantation (TIL-GVHD)

Status: Recruiting
Location: See location...
Intervention Type: Biological
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Graft versus Host Disease (GVHD) is frequent after allogeneic stem cell transplantation (alloSCT). GVHD occurs following 2 patterns : acute GVHD (aGVHD) or chronic GVHD (cGVHD). The latter occurs in nearly 50% of patients and its pathogenesis remains poorly understood. Previous translational studies have delineated biological immune dysregulation involved in cGVHD and facilitated the development of new drug and therapeutic strategies. New aspects of T and B cells collaboration in the context of cGVHD using blood description of a key player called TFH, classicaly involved in germinal center reaction, were previously uncovered (Forcade et al, Blood 2016). Previous studies in the context of auto-immune inflammation (lupus nephritis) or organ transplant rejection, suggested that target tissue could contain accessory lymphoid structures (TLS). The description of such structures in cGVHD target tissue would give the opportunity to directly analyze immune key player involved the pathogenesis of cGVHD.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Patient \> 18 yo ;

• Having undergone an allogeneic stem cell tranplant ;

• 2 groups of patients will be eligible

• showing evidence of primary cGVHD or occuring after Donor Lymphocyte Infusion

‣ in the case of first occurrence of cGVHD, in the absence of any new systemic therapy ;

⁃ in the case of recurrent cGVHD, steroid dose has to be below 15mg/day of Prednisone ;

• Having read, understood and signed an informed consent of the study;

• With social security affiliation;

Locations
Other Locations
France
CHU de Bordeaux, Service d'Hématologie Clinique et Thérapie Cellulaire
RECRUITING
Pessac
Contact Information
Primary
Edouard FORCADE
edouard.forcade@chu-bordeaux.fr
+33557656511
Time Frame
Start Date: 2024-05-21
Estimated Completion Date: 2026-06
Participants
Target number of participants: 70
Treatments
Other: Patients with cGVHD
Other: Patients without cGVHD
Sponsors
Leads: University Hospital, Bordeaux

This content was sourced from clinicaltrials.gov